Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Azienda Ospedaliero-Universitaria Careggi · University of Florence · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,180
total citations
- FWCI
- 74.80
- Percentile
- 100%
- References
- 30
Citations per year
Authors
99- IOIacopo OlivottoCorresponding
Azienda Ospedaliero-Universitaria Careggi, University of Florence
- AOArtur Oręziak
Institute of Cardiology
- RBRoberto Barriales‐Villa
Universidade da Coruña, Centro de Investigación Biomédica en Red, Complexo Hospitalario Universitario A Coruña, Servicio Gallego de Salud, Instituto de Investigación Biomédica de A Coruña
- TPTheodore P. Abraham
University of California, San Francisco
- AMAhmad Masri
Oregon Health & Science University
Topics & keywords
Topics
Keywords
- Placebo
- Hypertrophic cardiomyopathy
- Medicine
- Internal medicine
- Cardiology
- Double blind
- Randomized controlled trial
- Pathology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.